...
首页> 外文期刊>British Journal of Haematology >Management of autoimmune diseases after haematopoietic stem cell transplantation
【24h】

Management of autoimmune diseases after haematopoietic stem cell transplantation

机译:造血干细胞移植后自身免疫疾病的管理

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Autologous and allogeneic haematopoietic stem cell transplantation (HSCT) is an option for the treatment of malignant and non-malignant diseases, including the severe autoimmune diseases. Intriguingly, the 'new' autoimmunity developing after transplantation is a constantly recognized phenomenon, which has to be differentiated from original disease relapse, toxicity, infection and graft-versus-host disease. The reported autoimmune diseases occurring in this setting are mainly antibody-associated and organ-specific, with scarce evidence in support for specific treatment options. This review focuses on current concepts on the pathogenesis, the available data on incidence, risk factors, manifestations and treatment of post-HSCT autoimmune diseases.
机译:自体和异体造血干细胞移植(HSCT)是治疗恶性和非恶性疾病(包括严重的自身免疫性疾病)的一种选择。有趣的是,移植后发展出的“新”自身免疫是一个一直公认的现象,必须与原始疾病的复发,毒性,感染和移植物抗宿主病区分开。据报道,在这种情况下发生的自身免疫性疾病主要是抗体相关和器官特异性的,缺乏支持特定治疗选择的证据。这篇综述着重于当前的发病机理,HSCT后自身免疫性疾病的发病率,危险因素,表现和治疗的可用数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号